HLVX
NASDAQHilleVax Inc.
Price$2.10+0.18 (+9.11%)
2025-06-122025-09-16
Latest news
25 items- SECSEC Form 15-12G filed by HilleVax Inc.15-12G - HilleVax, Inc. (0001888012) (Filer)
- SECSEC Form EFFECT filed by HilleVax Inc.EFFECT - HilleVax, Inc. (0001888012) (Filer)
- SECSEC Form EFFECT filed by HilleVax Inc.EFFECT - HilleVax, Inc. (0001888012) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by HilleVax Inc.SCHEDULE 13D/A - HilleVax, Inc. (0001888012) (Subject)
- INSIDERSEC Form 4 filed by Large owner Takeda Pharmaceutical Co Ltd4 - HilleVax, Inc. (0001888012) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by HilleVax Inc.SCHEDULE 13D/A - HilleVax, Inc. (0001888012) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by HilleVax Inc.SCHEDULE 13D/A - HilleVax, Inc. (0001888012) (Subject)
- INSIDERSEC Form 4 filed by Large owner Frazier Life Sciences X, L.P.4 - HilleVax, Inc. (0001888012) (Issuer)
- SECSEC Form S-8 POS filed by HilleVax Inc.S-8 POS - HilleVax, Inc. (0001888012) (Filer)
- SECSEC Form POS AM filed by HilleVax Inc.POS AM - HilleVax, Inc. (0001888012) (Filer)
- SECSEC Form POS AM filed by HilleVax Inc.POS AM - HilleVax, Inc. (0001888012) (Filer)
- INSIDERDirector Cocero Nanette closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERDirector Hilleman Jeryl L closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERDirector Dubin Gary closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERDirector Chu Shelley closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERPresident and CEO Hershberg Robert closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERDirector Gerberding Julie L. closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERChief Financial Officer Maltbie Shane closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERDirector Sepulveda Jaime closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- INSIDERDirector Kohli Aditya closing all direct ownership in the company (SEC Form 4)4 - HilleVax, Inc. (0001888012) (Issuer)
- SECSEC Form 25-NSE filed by HilleVax Inc.25-NSE - HilleVax, Inc. (0001888012) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by HilleVax Inc.SC 14D9/A - HilleVax, Inc. (0001888012) (Subject)
- SECHilleVax Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update8-K - HilleVax, Inc. (0001888012) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by HilleVax Inc.SC TO-T/A - HilleVax, Inc. (0001888012) (Subject)
- PRXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ:HLVX) ("HilleVax") common stock for a price per share of $1.95 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price"). The tender offer and related withdrawal rights expired one minute after 11:59
HLVX FAQ
7 questionsWhat does HilleVax Inc. do?
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.Where does HLVX stock trade?
HilleVax Inc. (HLVX) is listed on NASDAQ.What sector and industry is HLVX in?
HilleVax Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did HilleVax Inc. go public?
HilleVax Inc. (HLVX) completed its IPO in 2022.What are analysts saying about HLVX?
HilleVax Inc. has had 6 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $200.00 price target on 2024-07-09.What companies are similar to HLVX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare HLVX side-by-side with any of them on Quantisnow.How can I track HLVX on Quantisnow?
Quantisnow aggregates HilleVax Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HLVX to receive live email and push alerts on every new disclosure.